Floatz logo

Ropinirole

Restless Legs Syndrome

GlaxoSmithKlineSmall moleculePhase 4 / ApprovedDormant
A
81/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
72/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Restless Legs Syndrome cohort.

Asset / SponsorPhaseRating
FERRIC CATION
University of Zurich
Phase 4BBB
IRON(II) SULPHATE (1:1), HEPTAHYDRATE
Mayo Clinic
Phase 4BB
VITAMIN D
University of Sao Paulo General Hospital
Phase 4BB
Ctc-501
Massachusetts General Hospital
Phase 4BB
Ferumoxytol
Auerbach Hematology Oncology Associates P C
Phase 2B
Marcaine Injectable Product
Lowcountry Infectious Diseases
N/AD
LIDOCAINE
Lowcountry Infectious Diseases
N/AD
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
GlaxoSmithKline
D

Same molecule, other indications

Ropinirole is also rated in:

Parkinson diseaseDormant
BBB
Indicative ·
76 / 100
View asset →
drug-induced dyskinesiaDormant
BB
Indicative ·
64 / 100
View asset →
cirrhosis of liverDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →